8 research outputs found
Giant cell tumor of the fifth lumbar vertebra with a three-year follow-up: case report and review of the literature
We report the case of a patient with giant cell tumor of the L5
vertebra. A 35-year-old female patient with giant cell tumor of the L5
vertebra was subjected to a combined treatment. Three years after
treatment, there is no recurrence of the disease and no increase in the
residual tumor’s size. Giant cell tumor of the L5 vertebra requires
careful planning of treatment and close follow-up of the patient
Acute Infrarenal Aortic Thrombosis Presenting With Flaccid Paraplegia
Study Design. This study is a case report.
Objective. To report a case of a patient with paraplegia and low back
pain, who was diagnosed with acute infrarenal aortic thrombosis.
Summary of Background Data. There have been few reports in the
literature regarding acute aortic thrombosis presenting with paraplegia.
Methods. A 56-year-old man was referred to our emergency department with
flaccid paraplegia and low back pain. Clinical examination and imaging
revealed acute infrarenal aortic thrombosis, with lower limb ischemia.
The patient underwent transcutaneous embolectomy.
Results. Despite successful revascularization, the patient finally died
because of development of revascularization syndrome.
Conclusion. Acute aortic occlusion is a catastrophic event and may
present with paraplegia, because of acute spinal cord ischemia. This can
mislead the clinician to a wrong diagnosis and delay initiation of
definite treatment
Periprosthetic Knee Infections Treated with Irrigation and Debridement: Outcomes and Preoperative Predictive Factors
Surgical approach does not affect deep infection rate after primary total hip arthroplasty.
Teriparatide Treatment in Patients with Pregnancy- and Lactation-Associated Osteoporosis
Pregnancy- and lactation-associated osteoporosis (PLO) is a rare
disease, presenting in most cases with severe back pain due to low
energy vertebral fractures (VFs). Our purpose was to assess the effect
of teriparatide (TPTD) vs. conventional management on areal bone mineral
density (aBMD) and trabecular bone score (TBS) in patients with PLO. A
multicenter retrospective cohort study concerning premenopausal women
with PLO. Nineteen women were treated with TPTD (20 mu g/day) (group A)
plus calcium and vitamin D and eight women with calcium and vitamin D
only (group B) for up to 24 months. The primary end-point was between
group differences in lumbar spine (LS) and total hip (TH) aBMD, and TBS
at 12 and 24 months. Patients in group A had sustained a median of 4.0
VFs (3-9) vs. 2.5 VFs (1-10) in group B (p = 0.02). At 12 months,
patients on TPTD vs. controls achieved a mean aBMD increase of 20.9 +/-
11.9% vs. 6.2 +/- 4.8% at the LS (p < 0.001), 10.0 +/- 11.6% vs. 5.8
+/- 2.8% at the TH (p = 0.43), and 6.7 +/- 6.9% vs. 0.9 +/- 3.7% in
TBS (p = 0.09), respectively. At 24 months, seven patients on TPTD and
six controls achieved a mean LS aBMD increase of 32.9 +/- 13.4% vs.
12.2 +/- 4.2% (p = 0.001). P1NP levels during the first month of TPTD
treatment were positively correlated with the 1-year LS aBMD change (r =
0.68, p = 0.03). No new clinical fractures occurred while on-treatment.
In patients with PLO, TPTD treatment resulted in significantly greater
increases in LS aBMD compared with calcium and vitamin D supplementation
at 12 and 24 months